Skip to main content
Signal8
PR Newswire releases

BRAINBox Solutions to Present Data Supporting Multimodal Concussion Diagnostic/Prognostic Testing in Geriatric and Young Adult Patient Populations

Published Updated

Source: PR NewswireView original on PR Newswire

Studies to be presented at Emergencies in Medicine Conference (Maui)

RICHMOND, Va., Nov. 17, 2026 /PRNewswire/ -- BrainBox Solutions announced today that the company and its academic collaborators on HeadSMART clinical trials will present data at the Emergencies in Medicine Conference (Maui), December 6-9, supporting multi-modal concussion diagnostic/prognostic testing in geriatric and adolescent populations. The data, in poster presentations, are from substudies of the company's HeadSMART II and HeadSMART Geriatric clinical trials for the development of BRAINBox TBI tests to aid in the diagnosis and prognosis of concussion (also known as mild traumatic brain injury or mTBI, and Acute Traumatic Encephalopathy or ATE).

"Assessments of mTBI for both diagnostic and prognostic purposes rely on qualitative or subjective measures, which present distinct challenges to assessing TBI injury and longer-term risk in these patient groups," said W. Franklin Peacock MD, FACEP, Principal Investigator, and Professor of Emergency Medicine in the Department of Emergency Medicine at Baylor College of Medicine, an author on both of the studies. "The study in sports related injury supports the potential of an objective multi-modal test in sports sideline and clinical settings, and the trial in older adults suggests the potential stratifying risk by integrating quantitative imaging along with biomarkers and neurocognitive testing."

"Presentation of these early studies in older adults and in older adolescents with sports related concussions at prestigious forums such as the Emergencies in Medicine Conference, are part of our broader efforts to keep key medical stakeholders abreast of our program to develop the first objective concussion tests for all age groups," said Donna Edmonds, CEO of BRAINBox Solutions. "We expect to continue presenting data from these ongoing HeadSMART trials."

HeadSMART II Substudy: Sports-Related Concussion vs. Other Mechanisms in Young Adults

This study is aimed at the development of an AI-enabled objective test incorporating blood biomarkers and neurocognitive testing suitable for rapid, point-of-care evaluation by appropriate clinical or technically trained professionals (e.g. at sports sidelines) or by emergency department clinicians. Specifically, the study assessed whether models trained on adults (age 21-50) generalize to individuals 18-20 years old, which are a surrogate for adolescents for sports-related injury. The study found that a panel of three biomarkers (ST2, GFAP, and NRGN), combined with neurocognitive testing (BrainCheck®) distinguished between mTBI+ or mTBI-, including those with adolescent athletes.

Use of Routine Emergency Head CT for Quantitative Atrophy Assessment in Older Adults with Traumatic Brain Injury

The researchers evaluated whether a company-developed algorithm to quantify imaging data from routine head CT scans could be used along with biomarkers and neurocognitive testing to risk stratify mTBI patients. CT scans are normally used for qualitative evaluations.

Using the algorithm, the researchers successfully derived brain volumetrics from standard-of-care head CT scans. The analysis identified specific atrophy patterns—including Alzheimer's-like, vascular, and frontal-predominant profiles—that are frequently invisible to conventional global metrics. Notably, they identified a high-risk subgroup (15% of the study population) characterized by convergent multi-region atrophy, elevated blood biomarkers, and cognitive decline, who demonstrated particularly poor recovery over three months. This technology offers the potential for a window for 2-week post-injury risk stratification, potentially allowing for more intensive monitoring and targeted rehabilitation.

About BRAINBox Solutions 

BRAINBox Solutions is developing the first AI‐enabled, multi‐modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, now commonly referred to as a concussion. The company seeks to establish a clinical best‐practice standard for the diagnosis and prognosis of concussion providing information which can support the ability to guide interventions. The initial product incorporates a panel of proprietary, blood biomarkers that can be read in a few moments on a point‐of‐care instrument or using standard laboratory systems, combined with a digital neurocognitive testing platform, to provide a composite TBI injury score. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team. Learn more at: www.brainboxinc.com

For more information, contact:
Donna Edmonds
CEO
1‐804‐724‐0009

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brainbox-solutions-to-present-data-supporting-multimodal-concussion-diagnosticprognostic-testing-in-geriatric-and-young-adult-patient-populations-302941193.html

Share this release

Source: PR NewswireView original on PR Newswire

Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.

    BRAINBox Solutions to Present Data Supporting Multimodal Concussion Diagnostic/Prognostic Testing in Geriatric and Young Adult Patient Populations | Signal8